FCGR2B and B-cell non-Hodgkin lymphoma: To test whether these antibodies are also efficacious with other cancer cells, we transfected the B cell lymphoma cell line Raji (FcγRIIB+PD-L1−MHC-II+CD155−) with OKT3, PD-L1, and CD155 and co-cultured the resultant cells (Raji OKT3 PDL1 CD155) with PBMCs in the presence of serial dilutions of test and control antibodies.